Physician

Robert E. Dinsmore, MD

According to 2025 Medicare claims, Robert Dinsmore, MD (NPI: 1285635912) practices hematology/oncology in the Kiryas Joel-Poughkeepsie-Newburgh, NY market, with the plurality of this provider's patient population coming from Orange, NY. This provider's primary affiliated billing organization is CRYSTAL RUN HEALTHCARE PHYSICIANS LLP (NPI: 1952376410; TIN: 133843560) and primary practice location at 10941-9998.

Dinsmore's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 920 traditional Medicare patients, billed 181,010 HCPCS/CPT codes, and received $3,731,002 in Medicare payments. The top billing code was 99213 (Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more). Part D data shows 4,361 prescription claims across 517 beneficiaries totaling $5,415,170 in drug costs, led by Revlimid (Lenalidomide). DME data shows 73 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $1,711,889 to $3,731,002. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,227,864 to $5,415,170. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $8,961 and ending at $4,987.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	958	101,524	$1,711,889
2016	926	135,169	$1,799,484
2017	937	117,646	$2,285,237
2018	927	121,343	$2,880,354
2019	951	162,371	$3,128,969
2020	861	176,680	$3,107,145
2021	898	173,068	$3,688,182
2022	856	146,790	$3,305,318
2023	972	205,943	$4,710,966
2024	920	181,010	$3,731,002

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	527	5,293	$1,227,864
2016	568	5,175	$2,016,694
2017	530	5,036	$1,738,861
2018	507	4,909	$2,411,652
2019	527	5,015	$3,375,700
2020	528	4,909	$3,585,511
2021	520	4,534	$3,236,145
2022	494	4,242	$3,036,049
2023	499	4,502	$4,320,277
2024	517	4,361	$5,415,170

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	75	327	$52,726
2016	90	286	$7,281
2017	40	175	$13,470
2018	56	198	$17,953
2019	18	147	$7,406
2020	N/R	114	$7,191
2021	N/R	127	$8,182
2022	N/R	216	$9,764
2023	N/R	142	$13,909
2024	N/R	73	$2,140

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	476	1,056	$68
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	423	895	$13
80053	Blood test, comprehensive group of blood chemicals	509	1,317	$10
36415	Insertion of needle into vein for collection of blood sample	601	1,709	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	585	1,593	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	43	1,204	$828,067
Tibsovo	Ivosidenib	23	690	$769,184
Pomalyst	Pomalidomide	21	588	$436,428
Xtandi	Enzalutamide	26	780	$354,891
Lenvima	Lenvatinib Mesylate	15	450	$323,368

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8700	Temozolomide, oral, 5 mg	N	N/R	15	$785
J8521	Capecitabine, oral, 500 mg	N	N/R	20	$720
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	27	$439
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	11	$196

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Robert E. Dinsmore, MD?

Tedicare shows public-source Medicare data for Robert E. Dinsmore, MD (NPI 1285635912), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert E. Dinsmore, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert E. Dinsmore, MD?

Robert E. Dinsmore, MD is linked to CRYSTAL RUN HEALTHCARE PHYSICIANS LLP (billing NPI 1952376410) in the available physician profile data.

Does Robert E. Dinsmore, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.